IP Library › Granted Patent US 7,166,709
Granted Patent B2
US 7,166,709 · App. 10/257,375 · Granted Jan 23, 2007

Haemostatically active preparation containing vWF and method for the production thereof

Assignee: Octapharma AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,166,709
App. No.
10/257,375
Granted
Jan 23, 2007
Kind
B2
Abstract

A process for preparing a hemostatically active preparation containing von Willebrand factor (vWF) from a fraction of human plasma by chromatographic purification of a vWF-containing plasma fraction on an anion-exchange material which has the anion-exchanging groups on grafted polymeric structures (tentacle materials), collecting a vWF-containing fraction, followed by purification of said fraction using gel permeation to prepare a purified thermally stable vWF-containing preparation; and heating the preparation for inactivating viruses.

Claims (10)

1. A process for preparing a hemostatically active preparation containing von Willebrand factor (vWF) from a fraction of human plasma by

a) chromatographic purification of a vWF-containing plasma fraction on an anion-exchange material which has the anion-exchanging groups on grafted polymeric structures (tentacle materials), collecting a vWF-containing fraction, characterized in that

b) purification of said fraction using gel permeation to prepare a purified thermally stable vWF-containing preparation follows, and

c) heating the preparation for 1–5 hours (h) at a temperature of more than 80° C. in a lyophilized state for inactivating viruses and is stable in an aqueous solution at room temperature for at least one week.

2. The process according to claim 1 , characterized in that the thermally stable preparation and the heated preparation exhibit only one peak in HPLC gel filtration analysis.

3. The process according to claim 1 , characterized in that the preparation is heated at a temperature of more than 90° C.

4. The process according to claim 1 , characterized in that the preparation is heated at a temperature of 100° C.

5. The process according to claim 1 , characterized in that the preparation is heated for 2–3 h.

6. The process according to claim 1 , characterized in that said purification by gel permeation is effective as a final measure for protein purification.

7. The process according to claim 1 , characterized in that said fraction is purified from pooled human plasma.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2002
From: JOSIC, DJURO; STADLER, MONIKA; GRUBER, GERHARD
To: OCTAPHARMA AG
Reel/Frame 013941/0877 →
Priority Claims (1)
EP 00108430 · Apr 18, 2000 · regional
Continuity (1)
Related Publication 20030138913A1 · Jul 24, 2003